Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Ocupress
Synonyms :
carteolol ophthalmic
Class :
Beta Blockers, Antiglaucoma
Dosage Forms & StrengthsÂ
Ophthalmic SolutionÂ
1%Â
Elevated Intraocular PressureÂ
Indicated for Chronic Open-Angle Glaucoma & Intraocular Hypertension:
Ophthalmic solution
Instill 1 drop into each affected eye twice a day
Safety and efficacy not establishedÂ
Refer adult dosingÂ
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
may increase the AV-blocking effect of beta blockers
may enhance the bradycardic effect of bradycardia causing agents
may enhance the bradycardic effect of bradycardia, causing agents
may enhance the bradycardic effect of bradycardia causing agents
may decrease the toxic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the orthostatic effect of beta blockers
bunazosin (Not available in the United States)
may enhance the orthostatic effect of beta blockers
may enhance the orthostatic effect of beta blockers
may enhance the orthostatic effect of beta blockers
may enhance the orthostatic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of beta blockers
may enhance the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of bradycardia-causing agents
may enhance the bradycardic effect of bradycardia-causing agents
may decrease the toxic effect of beta blockers
may decrease the toxic effect of beta blockers
may decrease the toxic effect of beta blockers
may decrease the toxic effect of beta blockers
may decrease the toxic effect of beta blockers
may increase the vasoconstrictive effect of beta blockers
may increase the vasoconstrictive effect of beta blockers
may increase the vasoconstrictive effect of beta blockers
may increase the vasoconstrictive effect of beta blockers
may increase the vasoconstrictive effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
may enhance the hypoglycemic effect of beta blockers
Actions and Spectrum:Â
carteolol is a non-selective beta-adrenergic receptor antagonist used to treat intraocular pressure associated with ocular hypertension and glaucoma. The mechanism of action of carteolol is to block the beta-adrenergic receptors located in the ciliary epithelium and the ciliary muscle in the eye, leading to a reduction in aqueous humor production and an increase in aqueous humor outflow. This results in a decrease in intraocular pressure. Â
carteolol ophthalmic is effective against open-angle and closed-angle glaucoma, the most common forms. It also effectively treats ocular hypertension, an elevated intraocular pressure without evidence of optic nerve damage or visual field loss. carteolol ophthalmic is available as eye drops administered topically to the eye.Â
Frequency definedÂ
>10%Â
Conjunctival hyperemia (25%)Â
Eye irritation (25%)Â
Burning sensation in the eye (25%)Â
Excessive tear production (25%)Â
1-10%Â
PhotophobiaÂ
PtosisÂ
Blurred and cloudy visionÂ
Decreased night visionÂ
Abnormal corneal stainingÂ
HypoglycaemiaÂ
AsthmaÂ
ImpotenceÂ
BlepharoconjunctivitisÂ
Contraindications/caution:Â
Contraindications:Â
Caution:Â
Pregnancy consideration: CÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Pharmacology:Â
Pharmacodynamics:Â
Pharmacokinetics:Â
AbsorptionÂ
carteolol is administered topically as eye drops and absorbed through the cornea into the aqueous humor. The rate and extent of absorption depend on various factors, including the dose, the duration of exposure, and the characteristics of the ocular surface. Â
DistributionÂ
After absorption, carteolol is distributed throughout the eye, binding to beta-adrenergic receptors in the ciliary epithelium and the ciliary muscle. It does not appear to cross the blood-brain barrier or the placenta, and it is not known whether it is excreted in breast milk. Â
MetabolismÂ
carteolol is metabolized primarily in the liver by oxidation and glucuronidation. The primary metabolites are inactive and are excreted primarily in the urine. The clearance of carteolol may be decreased in individuals with hepatic impairment. Â
Elimination and ExcretionÂ
carteolol and its metabolites are excreted primarily in the urine. The elimination half-life of carteolol is approximately 6-9 hours, and its effects on intraocular pressure can last up to 24 hours after administration.Â
Administration:Â
Patient information leafletÂ
Generic Name: carteolol ophthalmicÂ
Pronounced: [kar-TEE-oh-lol-off-THAL-mik]Â
Why do we use carteolol ophthalmic?Â
carteolol ophthalmic is primarily used to lower intraocular pressure in individuals with ocular hypertension or open-angle glaucoma. By reducing the production and increasing the outflow of aqueous humor in the eye, carteolol can help to prevent damage to the optic nerve and preserve visionÂ